Monopar Therapeutics

MNPR

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001645469

SEC filings (opens in a new tab)

In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 4 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.

Q3 2025 vs. Q2 2025

How the institutions holding Monopar Therapeutics changed between Q2 2025 and Q3 2025.

All holders in Q3 2025 All holders in Q2 2025

13F holders of MNPR: Q2 2025 compared with Q3 2025
Measure	Q2 2025	Q3 2025	Change
Holders	43	56	+13
Shares	3.18M	4.34M	+1.16M (+36.5%)
Value	$113.3M	$354.3M	+$241.0M (+212.7%)

New holders (16)

Institutions that held Monopar Therapeutics at the end of Q3 2025 but not at the end of Q2 2025.

Institutions new to MNPR in Q3 2025
Institution	Shares	Value	% of portfolio
Wellington Management Group LLP	231,463	$18.9M	0.00%
Deerfield Management Company, L.P. (Series C)	159,765	$13.0M	0.20%
Saturn V Capital Management LLC	155,370	$12.7M	2.78%
TCG Crossover Management, LLC	153,000	$12.5M	0.61%
Vivo Capital, LLC	90,500	$7.39M	0.59%
Driehaus Capital Management LLC	64,636	$5.28M	0.04%
EAM Investors, LLC	14,629	$1.19M	0.14%
Alyeska Investment Group, L.P.	12,215	$997.6K	0.00%
Goldman Sachs Group Inc	6,525	$532.9K	0.00%
Nuveen, LLC	4,221	$344.7K	0.00%
State Board of Administration of Florida Retirement System	3,508	$286.5K	0.00%
Tower Research Capital LLC (TRC)	552	$45.1K	0.00%
Russell Investments Group, Ltd.	337	$27.5K	0.00%
SRS Capital Advisors, Inc.	14	$1.14K	0.00%
GAMMA Investing LLC	11	$898	0.00%
CWM, LLC	5	$0	0.00%

Sold out (3)

Institutions that held Monopar Therapeutics at the end of Q2 2025 and filed for Q3 2025 without it.

Institutions that sold out of MNPR in Q3 2025
Institution	Shares, Q2 2025	Value, Q2 2025
Point72 Asset Management, L.P.	104,019	$3.72M
Citadel Advisors LLC	6,232	$223.0K
Raymond James Financial Inc	431	$15.4K